Squarepoint
CCCC icon

Squarepoint’s C4 Therapeutics CCCC Stock Holding History

Squarepoint’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$798K Buy
170,834
+130,170
+320% +$445K ﹤0.01% 3075
2026
Q1 		$107K Sell
40,664
-95,390
-70% -$225K ﹤0.01% 4055
2025
Q4 		$260K Buy
136,054
+125,955
+1,247% +$298K ﹤0.01% 3702
2025
Q3 		$22.4K Sell
10,099
-133,588
-93% -$321K ﹤0.01% 4281
2025
Q2 		$205K Buy
+143,687
New +$209K ﹤0.01% 3967
2024
Q4 		– Sell
-147,874
Closed -$843K – 5048
2024
Q3 		$843K Buy
147,874
+90,757
+159% +$546K ﹤0.01% 2729
2024
Q2 		$264K Sell
57,117
-79,710
-58% -$475K ﹤0.01% 3503
2024
Q1 		$1.12M Buy
136,827
+90,802
+197% +$704K ﹤0.01% 2509
2023
Q4 		$260K Buy
+46,025
New +$105K ﹤0.01% 3447
2023
Q3 		– Sell
-52,024
Closed -$143K – 3825
2023
Q2 		$143K Sell
52,024
-55,608
-52% -$179K ﹤0.01% 3294
2023
Q1 		$338K Buy
107,632
+52,911
+97% +$312K ﹤0.01% 2507
2022
Q4 		$323K Buy
54,721
+33,467
+157% +$277K ﹤0.01% 2530
2022
Q3 		$186K Sell
21,254
-15,344
-42% -$159K ﹤0.01% 2703
2022
Q2 		$276K Buy
36,598
+20,519
+128% +$181K ﹤0.01% 2323
2022
Q1 		$390K Buy
16,079
+3,078
+24% +$74.7K ﹤0.01% 2146
2021
Q4 		$419K Buy
+13,001
New +$514K ﹤0.01% 2257

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's CCCC Position: Q2 2026 in Review

Squarepoint increased its C4 Therapeutics (CCCC) stake by 320% in Q2 2026, buying an estimated $445K and bringing the position to 170,834 shares worth $798K. The position accounts for ﹤0.01% of the portfolio, ranked #3075.

Squarepoint first reported a position in CCCC in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.12M in Q1 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Squarepoint held 170,834 shares of C4 Therapeutics worth $798K as of Q2 2026.
  • Squarepoint bought 130,170 C4 Therapeutics shares in Q2 2026, an estimated $445K.
  • C4 Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3075 holding.
  • Squarepoint first reported a position in C4 Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Squarepoint's C4 Therapeutics position peaked at $1.12M in Q1 2024.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.